Prospective Clinicogenomic Program

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Lung Cancer
Trial Status:

Recruiting

This trial runs in
Cities
  • Athens
  • Atlanta
  • Birmingham
  • Chandler
  • Chattanooga
  • east-brunswick
  • east-syracuse
  • Fort Myers
  • Fort Wayne
  • Fredericksburg
  • Grand Rapids
  • Henderson
  • Huntsville
  • Lincoln
  • Nashville
  • New Haven
  • New York
  • port-jeff-sta
  • port-jefferson-station
  • Richmond
  • St. Petersburg
  • Tallahassee
  • Tulsa
  • West Palm Beach
Trial Identifier:

NCT04180176 GX41563

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.

      Genentech, Inc. Sponsor
      Phase 4 Phase
      NCT04180176 , GX41563 Trial Identifier
      Blood Draw Treatments
      Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC) Condition
      Official Title

      A Multicenter, Low-Interventional Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Documented diagnosis of mNSCLC or ES-SCLC
      • Planned initiation of SOC systemic anti-cancer treatment
      • Front-Line Immunotherapy Cohort: Received front-line treatment of an immune blockade therapy including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibody on Protocol GX41563
      Exclusion Criteria
        - Participant actively receiving investigational medicinal product(s) as part of an interventional trial at the time of signing informed consent

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now